IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-7.92%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$443M
AUM Growth
+$443M
(-1.2%)
Cap. Flow
-$154M
Cap. Flow
% of AUM
-34.63%
Top 10 Holdings %
Top 10 Hldgs %
47.3%
Holding
81
New
8
Increased
12
Reduced
20
Closed
11
Top Buys
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$19.3M |
| 2 |
Novavax
NVAX
|
$18.5M |
| 3 |
Zai Lab
ZLAB
|
$8.59M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$7.65M |
| 5 |
Sanofi
SNY
|
$7.64M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$51.4M |
| 2 |
Amgen
AMGN
|
$38.1M |
| 3 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$29.3M |
| 4 |
Insmed
INSM
|
$28.8M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$25.7M |
Sector Composition
| 1 | Healthcare | 99.23% |
| 2 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$155B
| $32.6M | 7.34% | 66,746 -78,000 | -54% | -$38.1M |
|
2
Prothena Corp
PRTA
$441M
| $23.8M | 5.38% | 15,000 | – | – |
|
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $21.7M | 4.9% | 38,000 -90,000 | -70% | -$51.4M |
|
|
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $20.9M | 4.72% | 50,956 -62,500 | -55% | -$25.7M |
|
5
Harmony Biosciences
HRMY
$2.12B
| $20.5M | 4.63% | 205,474 -30,526 | -13% | -$3.05M |
|
|
6
BioCryst Pharmaceuticals
BCRX
$1.74B
| $19.3M | 4.35% | +57,000 | New | +$19.3M |
|
|
7
Novavax
NVAX
$1.21B
| $18.5M | 4.18% | +132,500 | New | +$18.5M |
|
8
Rocket Pharmaceuticals
RCKT
$354M
| $17.9M | 4.03% | 63,000 | – | – |
|
9
Supernus Pharmaceuticals
SUPN
$2.53B
| $17.5M | 3.94% | 297,500 | – | – |
|
|
10
Zai Lab
ZLAB
$3.68B
| $17M | 3.82% | 78,958 +40,000 | +103% | +$8.59M |
|
|
11
Insmed
INSM
$28.8B
| $14.3M | 3.22% | 40,100 -81,000 | -67% | -$28.8M |
|
12
uniQure
QURE
$896M
| $11.8M | 2.66% | 155,500 | – | – |
|
13
Vera Therapeutics
VERA
$1.38B
| $11.6M | 2.62% | 190,749 +70,214 | +58% | +$4.27M |
|
|
ONC
14
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $11.4M | 2.57% | 15,700 -4,300 | -22% | -$3.12M |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $10.8M | 2.44% | 383,233 | – | – |
|
16
Illumina
ILMN
$15.8B
| $10.8M | 2.43% | 48,000 +10,500 | +28% | +$2.35M |
|
17
HUTCHMED
HCM
$2.58B
| $10.1M | 2.27% | 68,000 | – | – |
|
|
GMDA
18
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $9.99M | 2.25% | 107,000 | – | – |
|
|
BHVN
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $9.29M | 2.1% | 130,900 -9,000 | -6% | -$639K |
|
|
TPTX
20
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $8.68M | 1.96% | 14,093 -47,648 | -77% | -$29.3M |
|
21
Denali Therapeutics
DNLI
$2.23B
| $8.19M | 1.85% | 38,000 +12,000 | +46% | +$2.59M |
|
|
AVDL
22
Avadel Pharmaceuticals
AVDL
$1.43B
| $7.65M | 1.72% | +50,000 | New | +$7.65M |
|
|
23
Sanofi
SNY
$121B
| $7.64M | 1.72% | +31,500 | New | +$7.64M |
|
|
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.45M | 1.68% | 183,473 +83,600 | +84% | +$3.4M |
|
25
Jazz Pharmaceuticals
JAZZ
$7.75B
| $5.92M | 1.34% | 17,200 -27,000 | -61% | -$9.3M |
|